Michal Or-Guil
Overview
Explore the profile of Michal Or-Guil including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
223
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Blazquez-Navarro A, Roch T, Wehler P, Kaliszczyk S, Bauer C, Thieme C, et al.
Front Transplant
. 2024 Jul;
2:1188535.
PMID: 38993901
Human herpesvirus 6 (HHV-6) is a common opportunistic pathogen in kidney transplant recipients. Two distinct species of HHV-6, HHV-6A and HHV-6B, have been identified, of which the latter seems to...
2.
Rosiewicz K, Blazquez-Navarro A, Kaliszczyk S, Bauer C, Or-Guil M, Viebahn R, et al.
Front Transplant
. 2024 Jul;
3:1393838.
PMID: 38993745
Background: Mono and combined reactivation of latent viruses occurs frequently under immunosuppressive therapy in kidney transplant patients. Recently, monitoring torque teno virus (TTV) reactivation came more into focus as a...
3.
Blazquez-Navarro A, Roch T, Wehler P, Stervbo U, Bauer C, Wolk K, et al.
J Nephrol
. 2022 Dec;
36(4):1071-1073.
PMID: 36459372
No abstract available.
4.
Blazquez-Navarro A, Mittmann L, Thieme C, Anft M, Paniskaki K, Doevelaar A, et al.
J Nephrol
. 2022 Jul;
36(1):199-202.
PMID: 35779233
No abstract available.
5.
Blazquez-Navarro A, Bauer C, Wittenbrink N, Wolk K, Sabat R, Dang-Heine C, et al.
Curr Res Transl Med
. 2022 Feb;
70(3):103334.
PMID: 35193070
Purpose Of The Study: Long-term graft survival rates after renal transplantation are still poor. We aimed to build an early predictor of an established long-term outcomes marker, the estimated glomerular...
6.
Blazquez-Navarro A, Dang-Heine C, Wehler P, Roch T, Bauer C, Neumann S, et al.
Transpl Int
. 2021 Aug;
34(9):1680-1688.
PMID: 34448272
Epstein-Barr virus (EBV) reactivation is a very common and potentially lethal complication of renal transplantation. However, its risk factors and effects on transplant outcome are not well known. Here, we...
7.
Blazquez-Navarro A, Dang-Heine C, Bauer C, Wittenbrink N, Wolk K, Sabat R, et al.
Front Pharmacol
. 2021 Feb;
11:534681.
PMID: 33519427
Post-transplantation cytomegalovirus (CMV) syndrome can be prevented using the antiviral drug (val)ganciclovir. (Val)ganciclovir is typically administered following a prophylactic or a pre-emptive strategy. The prophylactic strategy entails early universal administration,...
8.
Wittenbrink N, Herrmann S, Blazquez-Navarro A, Bauer C, Lindberg E, Wolk K, et al.
BMC Immunol
. 2019 Apr;
20(1):11.
PMID: 31029086
Background: Acute cellular rejection (ACR) is associated with complications after kidney transplantation, such as graft dysfunction and graft loss. Early risk assessment is therefore critical for the improvement of transplantation...
9.
Blazquez-Navarro A, Dang-Heine C, Wittenbrink N, Bauer C, Wolk K, Sabat R, et al.
EBioMedicine
. 2018 Aug;
34:113-121.
PMID: 30072213
Background: BK virus (BKV), Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) reactivations are common after kidney transplantation and associated with increased morbidity and mortality. Although CMV might be a risk factor...
10.
Blazquez-Navarro A, Schachtner T, Stervbo U, Sefrin A, Stein M, Westhoff T, et al.
PLoS Comput Biol
. 2018 May;
14(5):e1005998.
PMID: 29746472
BK virus (BKV) associated nephropathy affects 1-10% of kidney transplant recipients, leading to graft failure in about 50% of cases. Immune responses against different BKV antigens have been shown to...